[Form 4] Acuren Corporation Insider Trading Activity

Rhea-AI Filing Summary

Form 4 snapshot: On 08/04/2025 Acuren Corp (TIC) director Byron Roth was granted 9,524 restricted stock units (RSUs) at an exercise price of $0.00.

The RSUs convert 1-for-1 into common shares and vest in full on 08/04/2026. After the grant Roth now beneficially owns 9,524 derivative securities, all held directly. No open-market buying or selling occurred, so the filing reflects routine equity compensation rather than a directional transaction.

Filed 08/06/2025, the disclosure is administrative, carries negligible dilution relative to total shares outstanding, and signals no change in control, strategy or near-term cash flow.

Insights

Financial Analyst

TL;DR – Routine insider RSU grant; neutral valuation impact.

The 9,524-unit award equals less than 0.1% of a typical small-cap share count and involves no cash exchange. Such grants align director incentives but are immaterial to earnings, liquidity or ownership concentration. No buy/sell signal is implied, so portfolio impact is neutral.

Corporate Governance Expert

TL;DR – Standard board compensation, no governance red flags.

Annual RSU awards with one-year vesting are common practice, encouraging director retention and alignment with shareholder value. The straight-line vesting period and direct holding structure conform to best-practice guidelines. No unusual acceleration clauses or related-party nuances appear.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roth Byron

(Last) (First) (Middle)

C/O ACUREN CORPORATION

14434 MEDICAL COMPLEX DRIVE, SUITE 100

(Street)

TOMBALL TX 77377

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACUREN CORP [ TIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/04/2025		A		9,524		(2)	(2)	Common Stock	9,524	$0.00	9,524	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

2. These restricted stock units vest on August 4, 2026 (the one-year anniversary of the grant date).

	/s/ MaryJo Obrien, Attorney-in-Fact	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Acuren (TIC) report on 08/06/2025?

The Form 4 shows director Byron Roth received 9,524 restricted stock units on 08/04/2025.

When do the newly granted TIC RSUs vest?

The RSUs fully vest on 08/04/2026, one year after the grant date.

Did the insider buy or sell Acuren shares for cash?

No. The filing reflects a non-cash equity grant; no shares were purchased or sold in the open market.

How many TIC shares does Byron Roth now beneficially own?

Following the grant he directly owns 9,524 RSU-linked derivative securities.

Does the Form 4 indicate any change in Acuren’s control or strategy?

No material control or strategic change is disclosed; the event is routine director compensation.